Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Life-threatening bleeding under vitamin K antagonists in spite of an INR in the therapeutic range.

× No keyword cloud information.

20 in total

Review 1. The molecular basis of blood coagulation.

Authors: B Furie; B C Furie
Journal: Cell Date: 1988-05-20 Impact factor: 41.582

2. Should patients starting anticoagulant therapy be screened for missense mutations at Ala-10 in the factor IX propeptide?

Authors: J Peters; R Luddington; K Brown; C Baglin; T Baglin
Journal: Br J Haematol Date: 1997-11 Impact factor: 6.998

3. Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy.

Authors: J Oldenburg; E M Quenzel; U Harbrecht; A Fregin; W Kress; C R Müller; H J Hertfelder; R Schwaab; H H Brackmann; P Hanfland
Journal: Br J Haematol Date: 1997-07 Impact factor: 6.998

4. No indication for APTT screening in patients on oral anticoagulant therapy.

Authors: F J van der Meer; H L Vos; F R Rosendaal
Journal: Thromb Haemost Date: 1999-03 Impact factor: 5.249

5. No impact of factor IX Ala-10 mutations in acenocoumarol-treated southern Europeans.

Authors: Dolors Tàssies; Joan Monteagudo; Santiago Maragall; Antoni Ordinas; Joan Carles Reverter
Journal: Blood Coagul Fibrinolysis Date: 2005-11 Impact factor: 1.276

6. Congenital hypersensitivity to vitamin K antagonists due to FIX propeptide mutation at locus -10: a (not so) rare cause of bleeding under oral anticoagulant therapy in Switzerland.

Authors: Silvia Ulrich; Brigitte Brand; Rudolf Speich; Johannes Oldenburg; Lars Asmis
Journal: Swiss Med Wkly Date: 2008-02-23 Impact factor: 2.193

Life-threatening bleeding under vitamin K antagonists in spite of an INR in the therapeutic range.

Review 1. The molecular basis of blood coagulation.

2. Should patients starting anticoagulant therapy be screened for missense mutations at Ala-10 in the factor IX propeptide?

3. Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy.

4. No indication for APTT screening in patients on oral anticoagulant therapy.

5. No impact of factor IX Ala-10 mutations in acenocoumarol-treated southern Europeans.

6. Congenital hypersensitivity to vitamin K antagonists due to FIX propeptide mutation at locus -10: a (not so) rare cause of bleeding under oral anticoagulant therapy in Switzerland.

7. A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism.

8. Recognition site directing vitamin K-dependent gamma-carboxylation resides on the propeptide of factor IX.

9. Life threatening bleeding under adequate oral anticoagulation. Cases 4a, b.

10. [Clinical problems with oral anticoagulation -- 3 case reports].